UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 237

Sortiert nach

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

Nature communications, 2021-05, Vol.12 (1), p.2498-2498, Article 2498

2021

Link zum Volltext

Verfügbarkeit prüfen

Correlations between diffusion-weighted imaging and breast cancer biomarkers

European radiology, 2012-07, Vol.22 (7), p.1519-1528

2012

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

Breast (Edinburgh), 2023-06, Vol.69, p.441-450

2023

Link zum Volltext

Verfügbarkeit prüfen

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

Cancers, 2019-10, Vol.11 (11), p.1661

2019

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

BMC cancer, 2011-01, Vol.11 (1), p.31-31, Article 31

2011

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives

Cancers, 2022-04, Vol.14 (9), p.2136

2022

Link zum Volltext

Verfügbarkeit prüfen

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

International journal of molecular sciences, 2022-11, Vol.23 (21), p.13604

2022

Link zum Volltext

Verfügbarkeit prüfen

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas

Genome medicine, 2022-08, Vol.14 (1), p.1-98, Article 98

2022

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

The New England journal of medicine, 2015-04, Vol.372 (17), p.1672-1673

2015

Link zum Volltext

Verfügbarkeit prüfen

Dysgeusia in Patients with Breast Cancer Treated with Chemotherapy-A Narrative Review

Nutrients, 2023-01, Vol.15 (1), p.226

2023

Link zum Volltext

Verfügbarkeit prüfen

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer

Cancers, 2022-05, Vol.14 (10), p.2468

2022

Link zum Volltext

Verfügbarkeit prüfen

Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients

Breast (Edinburgh), 2024-06, Vol.75, p.103713-103713, Article 103713

2024

Link zum Volltext

Verfügbarkeit prüfen

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer

Cell reports (Cambridge), 2015-04, Vol.11 (4), p.564-576

2015

Link zum Volltext

Verfügbarkeit prüfen

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice

Frontiers in oncology, 2022-10, Vol.12, p.1032166-1032166

2022

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab emtansine in HER2-positive metastatic breast cancer

The lancet oncology, 2017-06, Vol.18 (6), p.696-697

Montemurro, Filippo

2017

Link zum Volltext

Verfügbarkeit prüfen

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations

EClinicalMedicine, 2023-08, Vol.62, p.102113-102113, Article 102113

2023

Link zum Volltext

Verfügbarkeit prüfen

Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal

Breast (Edinburgh), 2020-10, Vol.53, p.181-188

2020

Link zum Volltext

Verfügbarkeit prüfen

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

Expert opinion on biological therapy, 2007-02, Vol.7 (2), p.257-268

2007

Link zum Volltext

Verfügbarkeit prüfen

Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy

Endocrine-related cancer, 2009-12, Vol.16 (4), p.1091-1102

2009

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Cancers, 2023-12, Vol.16 (1), p.117

2023

Link zum Volltext

Verfügbarkeit prüfen

Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?

The lancet oncology, 2020-01, Vol.21 (1), p.21-24

2020

Link zum Volltext

Verfügbarkeit prüfen

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach

Frontiers in oncology, 2022-09, Vol.12, p.950861-950861

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 237

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(220)
Mit Volltextzugriff
(204)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(157)
Life Sciences & Biomedicine
(152)
Humans
(120)
Oncology
(112)
Female
(107)
Breast Cancer
(86)
Breast Neoplasms - Drug Therapy
(78)
Trastuzumab
(55)
Middle Aged
(54)
Adult
(49)
Breast Neoplasms - Pathology
(46)
Aged
(45)
Chemotherapy
(37)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(33)
Tumors
(31)
Treatment Outcome
(29)
Patients
(28)
Retrospective Studies
(27)
Prognosis
(26)
Receptor, Erbb-2 - Metabolism
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Correlations between diffusion-weighted imaging and breast cancer biomarkers

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Dysgeusia in Patients with Breast Cancer Treated with Chemotherapy-A Narrative Review

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer

PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology

Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice

Trastuzumab emtansine in HER2-positive metastatic breast cancer

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations

Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy

Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach

Suchergebnisse filtern